{"id":"azathioprine-and-allopurinol","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Allopurinol hypersensitivity syndrome"}]},"_chembl":{"chemblId":"CHEMBL1542","moleculeType":"Small molecule","molecularWeight":"277.27"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Azathioprine is a prodrug that is converted to 6-mercaptopurine, which inhibits de novo purine synthesis and reduces T-cell and B-cell proliferation, providing immunosuppressive effects. Allopurinol inhibits xanthine oxidase, the enzyme responsible for converting hypoxanthine and xanthine to uric acid, thereby reducing serum uric acid levels. This combination is used to manage conditions where both immunosuppression and uric acid reduction are therapeutically beneficial.","oneSentence":"Azathioprine suppresses the immune system by inhibiting purine synthesis, while allopurinol reduces uric acid production by inhibiting xanthine oxidase.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:42:16.165Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Autoimmune conditions requiring immunosuppression with concurrent hyperuricemia or gout prevention"}]},"trialDetails":[{"nctId":"NCT03101800","phase":"PHASE3","title":"Beneficial and Harmful Effects of Azathioprine and Allopurinol Versus Standard Azathioprine Therapy for Patients With Ulcerative Colitis","status":"UNKNOWN","sponsor":"Hvidovre University Hospital","startDate":"2016-12-14","conditions":"Colitis, Ulcerative, Colitis Ulcerative Exacerbation","enrollment":84},{"nctId":"NCT00849368","phase":"PHASE1","title":"Azathioprine & Allopurinol in Inflammatory Bowel Disease Patients","status":"COMPLETED","sponsor":"University of Zurich","startDate":"2009-01","conditions":"Inflammatory Bowel Disease","enrollment":6}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Azathioprine and Allopurinol","genericName":"Azathioprine and Allopurinol","companyName":"Hvidovre University Hospital","companyId":"hvidovre-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Azathioprine suppresses the immune system by inhibiting purine synthesis, while allopurinol reduces uric acid production by inhibiting xanthine oxidase. Used for Autoimmune conditions requiring immunosuppression with concurrent hyperuricemia or gout prevention.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}